Wednesday, July 8, 2026

Intelligence · Clinical Development

Pipeline search results

Programs matching “glucagon” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.

Matching programs 15
Total indexed 20,548
Sponsors 1,769

Quick answer

Showing 15 pipeline programs matching "glucagon" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.

Refine search

15 results for “glucagon” Back to intelligence hub

Search results

  1. Dasiglucagon 4 mg/ml

    Zealand Pharma A/S

    Children with congenital hyperinsulinism

    phase 3 small molecule active

    1 trial
  2. G-Pen (glucagon injection)

    Xeris Biopharma Holdings

    Hypoglycemia

    phase 3 small molecule completed

    1 trial
  3. Glucagon

    Xeris Biopharma Holdings

    Diabetes Mellitus, Type 1

    phase 3 small molecule completed

    1 trial
  4. G-Pen Mini™ (glucagon injection)

    Xeris Biopharma Holdings

    Diabetes Mellitus, Type 1

    phase 2 small molecule completed

    2 trials
  5. G-Pen Mini™ (glucagon injection)

    Xeris Biopharma Holdings

    Hypoglycemia

    phase 2 small molecule completed

    1 trial
  6. G-Pump™ (glucagon infusion)

    Xeris Biopharma Holdings

    Hypoglycemia

    phase 2 small molecule completed

    1 trial
  7. Glucagon

    Universal Integrated

    Hypoglycemia Unawareness

    phase 2 small molecule terminated

    1 trial
  8. Glucagon

    Xeris Biopharma Holdings

    Congenital Hyperinsulinism

    phase 2 small molecule completed

    1 trial
  9. Glucagon

    Xeris Biopharma Holdings

    Hypoglycemia

    phase 2 small molecule completed

    1 trial
  10. Glucagon RTU

    Xeris Biopharma Holdings

    Hyperinsulinemic Hypoglycemia

    phase 2 small molecule completed

    1 trial
  11. Glucagon RTU Injection With Insulin Pump Reduction

    Xeris Biopharma Holdings

    Hypoglycemia

    phase 2 small molecule completed

    1 trial
  12. glucagon

    Xeris Biopharma Holdings

    Post-bariatric Hypoglycemia

    phase 2 small molecule completed

    1 trial
  13. Glucagon

    United Therapeutics Europe Ltd

    Type 1 Diabetes Mellitus With Hypoglycemia

    phase 1 small molecule completed

    1 trial
  14. XeriSol glucagon

    Xeris Biopharma Holdings

    Type1diabetes

    phase 1 small molecule completed

    1 trial
  15. Glucagon-like peptide-1 receptor agonist:Semaglutide

    The First People's Hospital of Lianyungang

    Type 2 Diabetes

    approved small molecule active

    1 trial

Frequently asked questions

What is the Clinical Development Intelligence Platform?

It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.

How does this compare to Evaluate Pharma or Citeline?

Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.

Where does pipeline data come from?

Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.

Can I follow a company or program for updates?

Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.